Gartner Blog Network


Gartner 2015 Life Sciences Agenda Has Published

by Michael Shanler  |  February 15, 2015  |  Comments Off on Gartner 2015 Life Sciences Agenda Has Published

Last year, having spent an exceptional amount of quality time with clients, at conferences, and doing research, caused me to reflect on my teenage conversations with my grandparents.  Older, wiser people often talk about how knowledge, love (Happy Valentine’s Day, btw), courage, and making an impact on the world are the important things in life…but don’t forget time.  “Time is a very precious commodity.”

Within the analyst community, I’ve heard that only ~20% of what we know ever makes it into a piece of research because we don’t have enough time to write.   I’m not sure if this is conventional wisdom or a myth passed down from analyst generation to generation..…but IMHO  1% is a more appropriate figure.   Over the last few years, my number of engagements have skyrocketed with the addition of clinical development as a coverage area. But, I’m not complaining…  Having the entire R&D  spectrum of coverage is fantastic.  Visibility into both the “R” and the “D” process is essential.   Demand is a good thing for an analyst…but an extreme level of engagement carries costs-  I don’t have enough time to write about everything I want.     For 2015, I had to make some really tough decisions about what bodies of research to develop in written form, and which ones to hold onto behind the scenes.

The  Planned Research for Life Science Manufacturing, 2015 has the entire list.  It includes some patient, commercial, marketing, and some supply chain topics as well.   Here is a subset of my R&D-related commitments for 2015:

  • Digital Moments in R&D
  • The top 10 disruptive technologies for life science.
  • Big data business justifications
  • E-clinical vendors
  • eTMF Future
  • How to leverage contract research organization clinical IT capabilities
  • Regulated vs. nonregulated content systems
  • Identification of medicinal product (IDMP)
  • Clinical trial data transparency
  • “Shadow IT” as partners, not adversaries
  • ELN maturity model
  • Enterprise-level laboratory informatics “who’s who”
  • How to engaging laboratory IT services
  • R&D Cool Vendors, Life Science Cool Vendors, Prediction Reports, Hype Cycles, and other special reports.
  • “First takes,” based on noteworthy events for R&D. Note: In 2015, I’ve already written opinions on the Proteus-Oracle announcement for digital medical adherence using ingestible sensors and Core Informatics new cloud platform for laboratory informatics and scientific collaboration. As DIA approaches, I’m sure my editors will see a few more “first takes” as news hits the wire.

I usually have some wiggle room to squeeze in a few notes that are not on the ‘official’ agenda… I have a lot of other material in raw form –R&D innovation, R&D road-mapping, R&D data standards, R&D IT spending, IP management, analytics, big data practices, IoT, collaboration, crowd-sourcing, real world evidence (RWE), risk based monitoring (RBM), adaptive trials, scientific search, KM in R&D, 3D bio printing, sensors in devices,  wearable devices for trials,  robotics, CTMS landscape, RIMS and submissions landscape, clinical trial payments, etc.  Let me know what is relevant to you.

I just wish there was more time to get all the content into written form.

Additional Resources

Category: 3d-printing  analytics  clinical-development  ctms  data-and-analytics-strategies  eclinical  edc  engineering  epro  gartner  innovation  internet-of-everything  internet-of-things  iot  it  manufacturing  nexus-of-forces  nof  pharmaceutical  product-development  rd  science  wearables  

Michael Shanler
Research VP
5 years at Gartner

Michael Shanler covers life science R&D technologies. Read Full Bio




Comments are closed

Comments or opinions expressed on this blog are those of the individual contributors only, and do not necessarily represent the views of Gartner, Inc. or its management. Readers may copy and redistribute blog postings on other blogs, or otherwise for private, non-commercial or journalistic purposes, with attribution to Gartner. This content may not be used for any other purposes in any other formats or media. The content on this blog is provided on an "as-is" basis. Gartner shall not be liable for any damages whatsoever arising out of the content or use of this blog.